175 related articles for article (PubMed ID: 32759684)
1. MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models.
Patt A; Demoret B; Stets C; Bill KL; Smith P; Vijay A; Patterson A; Hays J; Hoang M; Chen JL; Mathé EA
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32759684
[TBL] [Abstract][Full Text] [Related]
2. Degree of
Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
[TBL] [Abstract][Full Text] [Related]
3. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
[TBL] [Abstract][Full Text] [Related]
4. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
[TBL] [Abstract][Full Text] [Related]
6. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.
Traweek RS; Cope BM; Roland CL; Keung EZ; Nassif EF; Erstad DJ
Front Oncol; 2022; 12():1006959. PubMed ID: 36439412
[TBL] [Abstract][Full Text] [Related]
7. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
[TBL] [Abstract][Full Text] [Related]
8. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.
Schöffski P; Lahmar M; Lucarelli A; Maki RG
Future Oncol; 2023 Mar; 19(9):621-629. PubMed ID: 36987836
[TBL] [Abstract][Full Text] [Related]
9.
Casadei L; Calore F; Braggio DA; Zewdu A; Deshmukh AA; Fadda P; Lopez G; Wabitsch M; Song C; Leight JL; Grignol VP; Lev D; Croce CM; Pollock RE
Cancer Res; 2019 Oct; 79(19):4911-4922. PubMed ID: 31387924
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 May; 34(3):1008-1018. PubMed ID: 33677797
[TBL] [Abstract][Full Text] [Related]
11. Cracking the riddle of dedifferentiated liposarcoma: is EV-MDM2 a key?
Casadei L; Pollock RE
Oncoscience; 2020 Jan; 7(1-2):10-13. PubMed ID: 32258243
[TBL] [Abstract][Full Text] [Related]
12. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
[TBL] [Abstract][Full Text] [Related]
13. Application of MDM2 Fluorescence In Situ Hybridization and Immunohistochemistry in Distinguishing Dedifferentiated Liposarcoma From Other High-grade Sarcomas.
Song MJ; Cho KJ; Lee JS; Song JS
Appl Immunohistochem Mol Morphol; 2017; 25(10):712-719. PubMed ID: 27028243
[TBL] [Abstract][Full Text] [Related]
14. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Creytens D; Van Gorp J; Speel EJ; Ferdinande L
Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
[TBL] [Abstract][Full Text] [Related]
17. Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status.
Makise N; Sekimizu M; Kubo T; Wakai S; Hiraoka N; Komiyama M; Fukayama M; Kawai A; Ichikawa H; Yoshida A
Am J Surg Pathol; 2018 May; 42(5):656-664. PubMed ID: 29309298
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Akiyama T; Iwata S; Sugaya J; Yoshida A; Kawai A; Kondo T
Hum Cell; 2022 May; 35(3):936-943. PubMed ID: 35292923
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
[TBL] [Abstract][Full Text] [Related]
20. Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.
Lu J; Wood D; Ingley E; Koks S; Wong D
Mol Biol Rep; 2021 Apr; 48(4):3637-3647. PubMed ID: 33893924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]